Vanguard Global Advisers »

Silverback Therapeutics shares owned by Vanguard Global Advisers

Quarter-by-quarter ownership of Silverback Therapeutics (SPRY) shares owned by Vanguard Global Advisers from 13F filings

Historical chart of Vanguard Global Advisers investment in Silverback Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Silverback Therapeutics held by Vanguard Global Advisers consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Silverback Therapeutics by Vanguard Global Advisers

Quarter filed Position value Share count Share price at filing
2026-03-31 $213k 27k 8.03

More positions owned by Vanguard Global Advisers

Vanguard Index Fds S&p 500 Etf Shs (VOO)
Vanguard Index Fds Total Stk Mkt (VTI)
NVIDIA Corporation (NVDA)
Apple (AAPL)
Microsoft Corporation (MSFT)
Amazon (AMZN)
Alphabet Cap Stk Cl A (GOOGL)
Broadcom (AVGO)
Alphabet Cap Stk Cl C (GOOG)
Vanguard Intl Equity Index F Ftse Emr Mkt Etf (VWO)
Meta Platforms Cl A (META)
Tesla Motors (TSLA)
Vanguard Specialized Funds Div App Etf (VIG)
Berkshire Hathaway Inc Del Cl B New (BRK.B)
JPMorgan Chase & Co. (JPM)

View all positions for Vanguard Global Advisers

Top funds holding Silverback Therapeutics

RA Capital Management
OrbiMed Advisors
Rubric Capital Management
Deerfield Management Company
Millennium Management
BlackRock
Standard Life Aberdeen
Sr One Capital Management
Vanguard Group
Franklin Resources
State Street Corporation
Vanguard Capital Management
UBS Group
Janney Montgomery Scott
Tyro Capital Management

View all funds holding Silverback Therapeutics